

## ORIGINAL ARTICLE

**The Emerging Role of microRNAs as Novel Diagnostic and Therapeutic Tools For Breast Cancer: a systematic review**Sara Mumtaz<sup>\*</sup>, Rida Fatima Saeed<sup>\*</sup>, Asma Saleem Qazi, Nosheen Akhtar, Uzma Azeem Awan**ABSTRACT**

**Objective:** A systematic review was conducted to evaluate recent studies performed on miRNAs as a diagnostic and therapeutic biomarker in breast cancer.

**Study Design:** Online standard databases like PubMed, EMBASE, Web of Science and COCHRANE library were searched to identify research articles relevant to the topic.

**Place and Duration of Study:** All online published studies between 2010-2020, in the scientific electronic databases were analyzed.

**Materials and Methods:** This review was performed according to PRISMA guidelines. Databases were systematically analyzed to explore the diagnostic and therapeutic potentials of miRNAs in breast cancer.

**Results:** We identified twenty-seven studies after literature search. We found six studies focused on diagnosis, sixteen on therapeutics and five on both diagnosis and therapeutics of miRNAs in breast cancer.

**Conclusion:** The combined data obtained in the present systematic review specify that miRNAs could serve as novel diagnostic and therapeutic biomarkers in breast cancer, whereas the practical relevance of the current results has yet to be established.

**Keywords:** Breast Cancer, Diagnostics, miRNA, Molecular Biomarkers, Therapeutics.

**How to cite this:** Mumtaz S, Saeed RF, Qazi AS, Akhtar N, Awan UA. *The Emerging Role of microRNAs as Novel Diagnostic and Therapeutic Tools For Breast Cancer: a systematic review.* Life and Science. 2023; 4(2): 105-115. doi: <http://doi.org/10.37185/LnS.1.1.268>

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.

**Introduction**

Female breast cancer has surpassed lung cancer as the cancer that is most frequently diagnosed in the world. Breast cancer was estimated to have caused 2.3 million new cases in 2020, accounting for 11.7% of all new cancer cases, and 684,996 of those cases were fatal.<sup>1</sup> The current conventional treatment modalities comprise chemotherapy as systemic treatments, surgery or radiation as local therapies, immunotherapy and targeted therapy.<sup>2</sup> Although

these therapeutic approaches have significantly increased the survival of breast cancer patients, their effects may have varied since some patients responded less favourably while others did, based on the specific subtype of cancer.<sup>3,4</sup> Additionally, there are few therapeutic options for some subtypes of breast cancer, including triple-negative breast cancer (TNBC), which is resistant to hormone therapy. High recurrence rates and distant metastases to the major organs such as the lungs and brain with poor outcomes are the major challenges associated with breast cancer. These results highlight the need for effective alternative methods for breast cancer prevention, prognosis prediction, and treatment.<sup>5</sup> MicroRNAs (miRNAs) are conserved non-coding single-stranded RNAs comprising roughly 19 to 24 nucleotides in length.<sup>6</sup> Over the last few years, miRNAs have gained major attention in cancer research due to their imperative role in tumor initiation and progression which has created the new prospect for early cancer diagnosis and therapies.<sup>7</sup> These miRNAs can serve as “tumor suppressor” or as “onco-gene” or could play a dual role depending on

Department of Biological Sciences  
National University of Medical Sciences  
PWD Campus, Islamabad, Pakistan

Correspondence:

Dr. Sara Mumtaz

Dr. Rida Fatima Saeed

Assistant Professor, Biological Sciences

National University of Medical Sciences

PWD Campus, Islamabad, Pakistan

E-mail: [sara.mumtaz@numspak.edu.pk](mailto:sara.mumtaz@numspak.edu.pk)

E-mail: [rida.saeed@numspak.edu.pk](mailto:rida.saeed@numspak.edu.pk)

Funding Source: NIL; Conflict of Interest: NIL

Received: Aug 13, 2022; Revised: Feb 06, 2023

Accepted: Feb 12, 2023

the tumor type and targeted gene.<sup>8</sup> More evidence suggests that specific miRNAs could make excellent options for the detection and treatment of breast cancer patients. Furthermore, miRNAs may be considered therapeutic targets, with suppression or restoration of a specific miRNA capable of causing an in-vivo response.<sup>9</sup> Several biological pathways such as transcription factors and the effect of mutated proteins have been demonstrated to alter the expression levels of miRNAs in breast cancer.<sup>10</sup> The objective of this systematic review is to collect and highlight the information on miRNAs in breast cancer, in order to assess its potential role as diagnostic or therapeutic biomarkers.

### Materials and Methods

The current systematic review was conducted according to the guideline of the PRISMA 2020 statement (Table 1 – Supplementary table for PRISMA 2020 checklist).<sup>11</sup> The search was performed using a combination of terms related to miRNA-based diagnostic and therapeutic biomarkers for breast cancer. All published studies, in the scientific electronic databases of PubMed, EMBASE, Web of Science and COCHRANE library, were analyzed on 5<sup>th</sup> May 2021.

#### Inclusion Criteria

The databases were searched to identify research articles published between 2010-2020. An inclusion criterion was based on the following keywords: miRNAs, molecular biomarker, breast cancer, diagnostic and therapeutic. All research articles published in English were included only.

Exclusion criteria (1) studies not performed on breast cancer (2) breast cancer metastasize to other organs (3) studies that focus on the prognostic role of miRNAs (4) studies based on bioinformatics and nano-theranostic approaches (5) meta-analysis, review papers, conference abstract, clinical trials, letter to editors, comments, case reports, and duplicated publications.


#### Data Extraction

In the data extraction, we included the miRNA name, its diagnostic and therapeutic significance in breast cancer, role in cancer as tumor suppressor or oncogene, its biological effect, miRNA replacement therapy or inhibition therapy and the reference. The most important factor for the data extraction was miRNA and their diagnostic and therapeutic role in

breast cancer. All data processing and screening was done manually. Throughout the assessment processes, the authors and reviewers remained unbiased.

### Results

The detail selection process, done by using four databases (EMBASE, PubMed, COCHRANE Library and Web of Science) is depicted in Figure 1.



**Fig 1: PRISMA flow diagram of study selection process**

A total of 1911 papers were identified from 2010 to 2020. In these 1911 articles, 5 articles were found duplicates and 1585 were found irrelevant, as per the exclusion criteria of the study. The excluded articles include reviews (640), conferences (135), book chapters (281), clinical trials (11), non-English literature articles (2), correspondence (1), meta-analysis (1), and others (514). Then, 321 articles were further screened based on their abstract and paucity of adequate information, of which 290 were removed because they didn't fulfill the inclusion criteria. The remaining 30 articles were shortlisted for the present study in which 27 articles were included after excluding three studies based on full text read (Table 1).

In this review we focused on the breast cancer types, patient stage of cancer, ethnicity, signaling pathways and the expression of miRNAs as oncogenes or tumour suppressors.

Overall 16 miRNAs (miR-125, miR-205, miR-424, miR-489, miR-200a, miR-203, miR-542-3p, miR-

1179, miR-3188, miR-4306, miR-362-5p, miR-203b-3p, miR-203a-3p, miR-34a, miR-127, miR-429) were identified with therapeutic application. A total of six miRNAs (let-7, miR-195, miR-10b, miR-34a, miR-125b, miR-99a-5p) were reported to have diagnostic significance. The remaining five miRNAs (miR-105, miR-502-5p, miR-370, miR-25-3p, miR-30d) were reported to have miRNAs application as both diagnostic and therapeutic biomarkers (Table 1).

**Table 1: List of miRNAs and associated biological functions in breast cancer**

S.No	miRNA	Breast cancer type	Biological role	References
1	let-7	TNBC and luminal tumors	Tumor suppressor	12
2	miR-195	TNBC and luminal tumors	Tumor suppressor	12
3	miR-10b	Unclassified BC type	onco-miR	13
4	miR-34a	Unclassified BC type	Tumor suppressor	14
5	miR-125b	Unclassified BC type	Tumor suppressor	14
6	miR-99a-5p	Unclassified BC type	Tumor suppressor	15
7	miR-125b	Unclassified BC type	Tumor suppressor	16
8	miR-205	Unclassified BC type	Tumor suppressor	16,17
9	miR-424	Unclassified BC type	Tumor suppressor and onco-miR	16
10	miR-489	Unclassified BC type	Tumor suppressor	18
11	miR-200a	TNBC	Tumor suppressor	19
12	miR-203	Unclassified BC type	Tumor suppressor	20
13	miR-542-3p	Unclassified BC type	Tumor suppressor	20
14	miR-1179	Unclassified BC type	Tumor suppressor	21
15	miR-3188	Unclassified BC type	onco-miR	22
16	miR-4306	TNBC	Tumor suppressor	23
17	miR-362-5p	TNBC	onco-miR	24
18	miR-203b-3p	Unclassified BC type	Tumor suppressor	25
19	miR-203a-3p	Unclassified BC type	Tumor suppressor	25
20	miR-34a	TNBC	Tumor suppressor	26
21	miR-127	TNBC	Tumor suppressor	27
22	miR-429	TNBC	Undefined	28

23	miR-105	Unclassified type	Undefined	29
24	miR-502-5p	Unclassified type	Tumor suppressor	30
25	miR-370	Unclassified type	Undefined	31
26	miR-25-3p	TNBC	Tumor suppressor	32
27	miR-30d	Unclassified BC type	Tumor suppressor and oncogene	33

TNBC, Triple negative breast cancer; miRNA, microRNA; BC, Breast Cancer

### Diagnostic Potential of miRNAs in Breast Cancer

Among the selected studies concentrated on the diagnostic potential of miRNA in breast cancer, the older one was published in 2017. Here, Qattan et al., recognized let-7 and miR-195 as tumor suppressor circulating miRNAs in TNBC.<sup>12</sup> They measured the plasma levels of miRNAs in disease-free individuals (34), TNBC (36) and luminal tumors (57) using RT-qPCR. Interestingly, their findings discovered raised levels of let-7 in luminal breast cancer patients and high levels of miR-195 in TNBC patient plasma.

Monroig-Bosque et al. designed a strategy using small molecules that affect the overexpression of miR-10b (SMIRs).<sup>13</sup> They demonstrated that linifanib (multi-tyrosine kinase inhibitor) might inhibit the expression of miR-10a significantly and inverse its oncogenic role *in vitro* and *in vivo* setting of breast cancer. Moreover, high levels of miR-10a reduced the effectiveness of linifanib by reducing its kinase inhibitory effect in breast cancer.<sup>13</sup>

Some studies were focused on miRNA role as a diagnostic biomarker with chemotherapy, such as the work done by Kassem et al. on 39 newly diagnosed Egyptian breast cancer patients.<sup>14</sup> They evaluated the plasma levels of miR-34a and miR-125b to anticipate the effect of neoadjuvant chemotherapy and found that miR-34a expression level was significantly higher in patients compared to controls. However, miR-125b expression level was insignificantly higher in responsive patients, suggesting miR-34a and miR-125b could be potentially non-invasive diagnostic biomarkers for breast cancer.

More recently, Garrido-Cano et al. analysed expression levels of miR-99a-5p in primary tumors and plasma of breast cancer patients and found, considerably, its lower levels in breast cancer tissues than in healthy breast tissues.<sup>15</sup> On the other hand,

they found that in the plasma miR-99a-5p levels were significantly higher than healthy controls, suggesting it is a non-invasive diagnostic biomarker for early detection of breast cancer.

#### **Therapeutic Potential of miRNAs in Breast Cancer**

With a collective assessment of shortlisted articles, it was found that miRNAs can serve as replacement therapy against other therapeutic targets, it can inhibit or suppress tumor growth and can cause combined effects with other miRNAs that affect the cancer growth and metastasis. Details of all shortlisted articles on miRNAs and their potential are summarized in Table 1.

In the oldest research, Vilquin et al. showed that aromatase inhibitor resistance was caused by upregulation of miR-125b using the miRNA microarray experiments.<sup>16</sup> They found that either miR-205 or miR-125b can be ectopically overexpressed in MCF-7aro cells line to produce resistance to anastrozole and letrozole and to activate the AKT/mTOR pathway. Also, in MCF-7aro cell line estrogen-independent growth properties can be conferred by increasing miR-125b expression levels. The authors also found that targeting miR-125b can overcome letrozole resistance and is a potential therapeutic target in aromatase inhibitors resistant breast cancers.

In 2016, Huo and his group identified expression profile of miR-205 in inflammatory breast cancer. They showed that this miRNA was reduced in tumor tissue only. Similar results were found in inflammatory breast cancer compared with non-inflammatory breast cancer tissue.<sup>17</sup> In this study, low levels of miRNA-205 were related to worse distant metastasis free and overall survival.

Patel et al. identified the potential role of miR-489, which was dysregulated miRNAs causing breast cancer progression and metastasis using the molecular studies.<sup>18</sup> They specifically noted that miR-489 was downregulated in HER2+ breast cancer by HER2 downstream signaling through MAP pathway and was associated with aggressive tumor phenotype. In another work by Kim et al. the miR-200a was reported as a promising therapeutic target for the treatment of TNBC.<sup>19</sup> It was identified in this research article that insulin like growth factors, which are mRNA binding protein, IMP 2/3 were overexpressed in TNBC and caused epithelial-

mesenchymal transition (EMT) and metastasis. IMP2/3 were direct targets of miR-200a via progesterone receptor (PR) mRNA destabilization and represents a novel double-negative feedback loop that suppresses the pro-metastatic activities in TNBC. Similarly, Lyu and colleagues studied that overexpression of HER3 diminished the expression levels of two *Survivin*-targeting miRNAs, miR-542-3p and miR-203.<sup>20</sup> While, its specific knockdown enhanced the expression of miR-542-3p and miR-203 in breast cancer cells. Consistently, a mimic of both miRNAs showed that miR-542-3p exhibited better results not only in *Survivin* inhibition, but also increased paclitaxel induced apoptosis especially in overexpressing breast cancer cells (HER2). Furthermore, the results designated that HER3 signaling upregulated *Survivin* by elimination of miR-203 and miR542-3p, with the better inhibition efficacy of miR-542-3p, due to its three binding sites on *Survivin* mRNA.

Li et al, further, investigated that overexpression of miR-1179 affects breast cancer cells proliferation, migration and invasion by targeting Notch signaling pathway.<sup>21</sup> Mechanistically, it was found that upregulation of miR-1179 inhibited Notch 1, Notch 4 and Hes1 expression, thus indicating a therapeutic role of miR-1179 in breast cancer cells.

Chen and Chen intended to investigate the role of miR-3188 in breast cancer development, which targets TUSC5 gene.<sup>22</sup> They showed that miR-3188 was upregulated and downregulated in breast cancer tissues and cell lines than in normal tissues and cell lines respectively. Furthermore, they transfected MCF-cells with miR-3188 inhibitor showed inhibition of cell proliferation, migration and stimulation of apoptosis. They also concluded that there is a direct association between overexpression of this miRNA and p-p38 expression. miRNA suppression significantly decreased the p-p38 expression and was used as a therapeutic agent.

Zhao et al. studied the transcriptional downregulation of miR-4306 and their effects on three main factors; estrogen receptor alpha (ER- $\alpha$ ), human epidermal growth factor receptor 2 (HER2) and PR of TNBC.<sup>23</sup> Functional assay was performed using in vitro analysis. The molecular mechanism with their therapeutic potential was also studied using the orthotopic mouse model. They found that

miR-4306 was transcriptionally regulated by ER- $\alpha$ , HER2 and PR and knocking down of these factors caused downregulation of miR-4306. Thus, low expression levels of miR-4306 were strongly associated with lymph node metastasis and poor survival rate of patients.

Zhang et al. emphasized on the biological role of miR-362-5p and found a substantially elevated levels of miR-362-5p in TNBC cells as compared to HER-2 overexpressing cells.<sup>24</sup> Further analysis was done on the miR-362-5p and its target gene Sema3A, and an inverse relationship between miR-362-5p and Sema3A were observed. In another study, focusing on miR-203a-3p and miR-203b-3p, by Aakko et al., They suggested that these miRNAs are among the c-Myc-regulated elements that can control the expression of Bcl-xl and thus can effect tumor cell sensitivity and paclitaxel therapy.<sup>25</sup>

Furthermore, Weng et al. identified miR-34a as a promoter in M1 polarization in TNBC, emphasizing that this miRNA modifies tumor microenvironment and heterogeneity. It was also reported by Weng and his colleagues that a ribosome binding protein (MCT-1), encoded by MCTS1 gene, coordinates ribosomal recycling with translation initiation and tissue growth.<sup>26</sup> MCT-1 antagonist in combination with expression of miR-34a can change the polarity and immune cells activation for improving the efficacy of TNBC. Overexpression of MCT-1 stimulates EMT and matrix metalloproteinase (MMP) activation in TNBC cells.

Latest work on miR-127, by Umeh-Garcia and colleagues, shown that its downregulation was associated with a decrease in patient survival.<sup>27</sup> The authors used a novel approach of miR-127 prodrug (miR-127<sup>PD</sup>). This prodrug is converted to functional miR-127-3p in TNBC cells, where it decreases the cells viability, motility and sensitizing cells to chemotherapy. Additionally, systemic delivery of miR-127<sup>PD</sup> suppresses tumor growth and spontaneous metastasis of TNBC cells. In a nutshell, this study revealed that miR-127 plays important role in suppression of tumor growth and metastasis of TNBC.

Finally, Cava and colleagues in 2020 found miR-429 was upregulated and functioned as an oncogene. It acts as a regulator of migration and invasion of cancer cells, which is required for HER2+ cell

proliferation, one of the major factors in breast cancer proliferation.<sup>28</sup> Also, they showed that miR-429 regulated HIF1 $\alpha$  pathway via directly targeting VHL mRNA; an important molecule for HIF1 $\alpha$  degradation. Moreover, they showed that silencing of miR-429 delayed tumor growth and might be used a therapeutic probe in HER2+ breast cancer.

### **miRNA Potential as Both Diagnostic and Therapeutic Biomarker in Breast Cancer**

Metastasis prediction and therapy are essential for improving the longevity of breast cancer patients, as metastatic breast cancer remains a heterogeneous disease with poor prognosis. Around 30% of women identified at an early stage have secondary progression. In this section, five original articles were discussed, and the selected miRNAs details are listed in Table 1.

As early as 2014, Zhou et al. used MDA-MB-231 and the MCF-10A cell lines for studying the role of miRNAs.<sup>29</sup> The group worked on miRNAs which function as gene regulation, and found that miRNAs were differentially secreted among the two lines. Amongst different miRNA, the major focused was miR-105, predicted by several algorithms (TargetScan, miRDB, and PicTar) to target TJP1 (tight junction protein 1; also recognized as zonula occludens 1 or ZO-1), a migration-related gene. They reported that miR-105 typically expressed and secreted by metastatic breast cancer cells, is an effective regulator of migration via targeting the tight junction protein ZO-1.

Sun et al. Studied different breast cancer cells and found that miR-502-5p was significantly downregulated in MCF-7 and MDA-MB-231 breast cancer cell lines.<sup>30</sup> Furthermore, they found that overexpression of TRAF2 abrogates miR-502-5p and causes death of breast cancer cells. Hence, their results suggested the role of miR-502-5p as a tumor suppressor and thus can be considered as a potential diagnostic and therapeutic biomarker for breast cancer.

Mollainezhad et al. addressed the expression of miR-370 in human breast cancer, using twenty-two fresh frozen tissues samples of normal and malignant tissues. An examination was carried out by using a quantitative real-time polymerase chain reaction method.<sup>31</sup> They observed an upregulated miR-370 in breast cancer tissues compared to normal adjacent tissues.

In another study, scientists elucidated the role of miR-25-3p in TNBC as diagnostic and therapeutic biomarker.<sup>32</sup> They showed that miR-25-3p is involved in tumor proliferation both *in vitro* and *in vivo*. For that, they measured miR-25-3p differential expression using qRT-PCR and found that miRNA was upregulated in TNBC and its suppression induced cell apoptosis. Interestingly, Han et al., demonstrated the potential importance of miR-30d and recommended it as a diagnostic biomarker and therapeutic target.<sup>33</sup> They worked on miR-30d-KLF-11-STAT3 pathway and found the biological function of this pathway in cell proliferation and metastasis of breast cancer. Their experimental outcomes demonstrated that the levels of miR-30d were enhanced in the breast cancer cell lines as compared to the non-tumor mammary gland cell line. Moreover, the miR-30d mimic showed increased survival rates in breast cancer cells, by promoting migration, invasion, mediating EMT and inhibiting apoptosis.

## Discussion

Most of the updated research studies concluded that miRNAs play vital roles in multiple biological processes, including cell apoptosis, invasion, migration and proliferation. Ultimately, adding tumor suppressor genes or oncogenes in different cancers.<sup>34-37</sup> Deregulated miRNAs can serve as diagnostic and therapeutic targets, as they are found to have imparting crucial roles in carcinogenesis of the breast cancer. Several studies are being carried out to evaluate the aforementioned properties of miRNAs. Here, we have studied comprehensively the role of miRNAs in diagnostics and therapeutics, through a systemic literature search. The study showed that miRNAs have strong diagnostic potential. Secondly, miRNAs have significance as therapeutics targets and thirdly, miRNAs levels can be used to predict the outcomes of chemotherapy. Overall, we have identified 27 articles that encompass the diagnostic and/or therapeutic role of miRNAs in breast cancers. Interestingly, the studies that highlighted the role of miRNA as therapeutics were more in number as compared to studies that evaluated them as diagnostic marker. We found that 16 studies demonstrated the significance of miRNAs in therapeutics while 6 studies recommended it as diagnostic markers. The results were remarkable and

suggested a path to improve the diagnostic and therapeutic strategies using miRNAs, in context to breast cancer. Herein, we will discuss all these molecules stated above, but as we consider that twin role of miRNA is of more value, the miRNAs with dual potential will be discussed in more detail.

One important miRNA, miR-105, plays role in a variety of cancers, including colorectal cancer with its oncogenic character<sup>38</sup>, esophageal<sup>39</sup>, and non-small lung cancer.<sup>40</sup> The significance of miR-105 has been documented in breast cancer by Li et al.<sup>41</sup> Zhou and colleagues in 2014 have demonstrated that miR-105 plays a vital role in destroying the barriers of vascular endothelium by targeting the tight cellular junctions at pre metastatic stage and later facilitating metastasis. It is also indicated that the miRNA possesses the diagnostic as well as therapeutic potential. As an anti-miR-105 treatment, it abolishes the niche adaptation of tumor derived miR-105 systemic effect and in monolayers of endothelium, it damages and destroys cellular integrity against metastasis as a natural barrier.<sup>29</sup> Another miRNA, a potential regulator of TRAF2, is miR-502-5p, which possesses dual role in breast cancer progression.<sup>30</sup> TRAF2 enhance tumor cell proliferation and promotes cell metastasis with an increased survival rate of cancer. Many studies reported that TRAF2 is also a critical mediator of NF-κB cell by directly interacting with NF-κB pathway.<sup>42</sup> It was also proposed by Sun et al. that miR-502-5p may also target oncogenic TRAF2 in breast cancer and thus act as a tumor-suppressor gene<sup>30</sup>.


Another type of miRNA, miR-370 had a controversial role in malignancies due to its varying levels, in multiple cancers.<sup>43,44</sup> Previous, studies documented that miR-370 targets critical proteins such as MAP3K8 and WNT10B (human cholangiocarcinomas)<sup>45</sup>, FOXO1 (prostate cancer)<sup>46</sup>, and transforming growth factor beta receptor II (gastric carcinoma).<sup>47</sup> Interestingly, miR-370 has been proposed as marker with dual value (diagnosis and therapeutic) in breast cancer by Mollainezhad et al.<sup>31</sup> Furthermore, our search showed that miR-25-3p is also a new diagnostic and therapeutic target in breast cancer. Chen and co-workers also indicated that it is oncogenic and exerts a crucial effect on TNBC progression.<sup>32</sup> miR-25-3p imparts the dual effects via targeting tumor suppressor B-cell

translocation gene 2 (BTG2). The BTG2, is reported to play important roles in cell cycle progression, proliferation, DNA damage repair and apoptosis.<sup>48,49</sup> miR-30d is among other miRNAs documented to act as both diagnostic biomarker and treatment targets in breast cancer. Han et al. reported that depending on krüppel-like factor 11 (KLF-1) and pSTAT3 levels, miR-30d plays pivotal roles in breast cancer progression<sup>33</sup>. It has been well documented that KLF-11 and STAT3 are involved in multiple cancers proliferation and progression.<sup>50</sup> Furthermore, there were few studies which either just emphasized on the diagnostic value of miRNAs or them as therapeutic targets. miR-99a-5p, miR-34a and miR-125b, miR-10b, hsa-miR-195 and let-7miR were highlighted as diagnostic makers by Garrito-Cano et al., Kassem et al., Monroig-Bosque et al. and Qattan et al., respectively.<sup>12-15</sup> Using different strategies, the authors concluded that each miRNA, as a biomarker, facilitates the detection of breast cancer. Some of them were recommended for early diagnosis while others were suggested for later stage usage. For example, hsa-miR-195 and let-7miR and miR-99a-5p were proposed for earlier detection of breast cancer. Among them, miR-99a is already been confirmed as a tumor suppressor and its overexpression is linked to inhibition of invasion, migration and proliferation in breast cancers. While, for the first time, Garrito et al. proposed that circulating miR-99a-5p is used as diagnostic biomarker in plasma of breast cancer patients.<sup>15</sup> Similarly, circulating levels of hsa-miR-195 and let-7 in plasma were found to be significantly higher than those of healthy individuals and thus proposed as diagnostic biomarker.<sup>12</sup> miRNAs, miR-34a and miR-125b also exhibited their potential to be used as diagnostic biomarker for breast cancer patients.<sup>14</sup> Many studies showed that both of these miRNAs are tumor suppressors and with breast cancer, their expression is down-regulated leading to inhibition of cell growth, invasion and migration. Kassem and his coworker found that miR-34a expression levels were comparatively higher in breast cancer patients as compared to their controls with p value <0.001 while miR-125b expression levels were insignificantly higher in breast cancer patients on contrary to their controls.<sup>14</sup> However, they further performed ROC curve analysis for diagnostic value of miR-125b

evaluation and found that its sensitivity was 66.7%, specificity was 70.0%, PPV was 90.6%, NPV was 41.2% and accuracy was 73.5%. Finally, the study concluded that miR-34a and miR-125b are significantly correlated and are non-invasive diagnostic biomarkers for breast cancer. Moreover, miR-10b is the first oncogenic miRNAs that impart a crucial role in tumor progression and metastasis with its oncogenic activity via downstream targets interactions, including HOXD10, NF1, KLF4, and PTEN.<sup>51-53</sup> Monroig-Bosque laboratory presented that miR-10b can be used for selecting breast cancer patients for linifanib treatment.<sup>13</sup>


Notably, many studies demonstrated the significance of miRNAs in breast cancer therapeutics. Our search retrieved 16 studies reporting the therapeutic values of miR-125b, miR-205, miR-424, miR-205, miR-489, miR-200a, miR-203, miR-542-3p, miR-3188, miR-1179, miR-4306, miR-362-5p, miR-203b-3p, miR-203a-3p, miR-34a, miR-127, miR-429. Mechanistically, some of the miRNAs are found involved in the signaling mechanism such as AKT/mTOR pathway (miR-125b or miR-205, HER2-SHP2-MAPK (miR-489), HER3 signaling (miR-203 and miR-542-3p), Notch signaling pathway (miR-1179). Alterations of downstream gene networks are associated with miRNAs deregulation and is a promising feature for underpinning different disease effects. Some miRNAs can target both tumor suppressors and oncogenes such as miR-205. Studies have shown that it has anti-metastatic and anti-tumoral effects, thus it has double therapeutic efficacy. Its oncogenic role was targeted using a miRNA-inhibition approach<sup>54</sup>, while its tumor-suppressive activity was exploited by a miRNA-replacement approach.<sup>55</sup> So, a context dependent role could be accepted for some miRNAs. This is a critical concern that must be carefully examined to derive an appropriate selection of miRNAs for therapeutic purposes and build reliable and safe miRNA-based treatment. In addition, miR-34a was reported as both therapeutic agent and as diagnostic biomarker.<sup>14,26</sup> Thus, miR-34a is also a member with dualistic application in breast cancer. The results exhibited that miRNAs exhibit great potential as the therapeutic agent, however, for RNA based therapeutic development, stability and delivery must be addressed to overcome main challenges.<sup>56</sup>

The accurate target delivery of miRNAs with more efficiency should be endorsed crossing multiple barriers such as enzyme degradation, blood clearance, and poor bioavailability. Also, miR-34a emerged as a tumor suppressor in our systematic review of literature. Studies have showed that it downregulates the oncogene expression in various cancer triggering pathways.<sup>57</sup> In vivo breast cancer models have shown an enhanced antitumoral immune response, increased antitumor effects, suppression in breast cancer cell migration and promoted antimetastatic activity by miR-34a replacement therapy.<sup>58</sup> Another therapeutic role of miR-34a is illustrated in Figure 2. The receptor CD95 also known as Fas, is a member of tumor necrosis factor (TNF) receptor superfamily, which has been shown as extracellular anti-apoptotic targets of miR-34a, resulting in decreased cancer cell growth and inhibited apoptotic signaling.<sup>59</sup> The miR-34a-apoptotic associated pathways in metastatic breast cancer involved upstream apoptotic signals, such as the Wnt and TGF- cascade.<sup>60</sup> With the advancement in cancer biology research, numerous cell cycle related gene targets of miR-34s, such as MDM4, and CDK6, have been discovered.<sup>61,62</sup> miR-10b was one of the first oncogenic miRNAs reported to play an important role in promoting tumor metastasis.<sup>51</sup> miR-10b was shown to be induced by the TWIST1 pathway, which then inhibits HOXD10 (a tumour suppressor) and promotes upregulation of RhoA and RhoC. This leads to Rhokinase activation and cytoskeleton reorganization, all of which are involved in promoting breast cancer invasion.<sup>63</sup>



**Fig 2: Role of miR-34a as a tumor suppressor. miR-34 affect important cellular activities by regulating key genes involved in cell signaling, apoptosis, proliferation and EMT metastasis**

The pathway is illustrated in Figure 3, including a few other targets/regulators which have been depicted. When compared to paired primary tumors, miR-10b is overexpressed in metastatic patients, particularly in lymph node metastasis.<sup>64</sup> Furthermore, the oncogenic activity of miR-10b was largely induced by direct interactions with downstream targets such as PTEN, KLF4, HOXD10 and NF1.<sup>53,65</sup> Studies on breast cancer models have shown that inhibiting the expression of miR-10b can efficiently suppress cancer cells proliferation, migration and invasion.<sup>51</sup> Thus, miR-10b emerges as a worthwhile therapeutic target in breast cancer treatment. A recent analysis showed that miRNAs have the potential to give important information in a clinical environment, exhibiting the ability to operate as both screening tools for the classification of high-risk patients and guiding the treatment decision-making process. Because of their capacity to control many genes in molecular pathways, miRNAs are critical prospects for new molecular targeted treatments. Our findings suggest that miR-34a and miR-125b expression levels might be useful non-invasive indicators for breast cancer diagnosis. Because of their unexpected stability and noninvasive detection, circulating miRNAs have gained popularity as cancer biomarkers in recent years. Furthermore, analysis by Chan et al., suggested that four miRNAs were found as important diagnostic indicators by comparing miRNA patterns between blood samples from breast cancer patients and healthy individuals.<sup>66</sup> As a result, miRNAs appear to be potential candidate biomarkers for the early diagnosis of breast cancer;



**Fig 3: Role of miR-10b in oncogenic signaling. miR-10b is involved in regulating tumorigenesis and metastasis. It initially downregulates various tumor suppressors, which eventually leading to cancer development**



However, further research is required to enhance the sensitivities and specificities of detection methods for circulating miRNAs. A growing body of data suggests that some miRNAs may potentially aid in the detection of breast cancer patients. Furthermore, certain miRNAs may be considered therapeutic targets, with suppression or restoration of a specific miRNA capable of generating an in vivo response. Among the limitations of the current endeavor, it must be highlighted that the search algorithm was largely in charge of the process, which focused mainly on the titles or headings of published articles in an attempt to provide more applicable results. Furthermore, because of variations in patient characteristics (race, age or tumor), as well as the use of different detection and isolation methods of miRNA expression varies, we found significant heterogeneity in our results. According to the findings of this comprehensive review, it is evident that the detection and targeting of miRNA might be able to meet the demand for independent, easily available diagnostic and therapeutic molecular markers for breast cancer therapy. The miRNAs chosen in this study can be utilized as a starting point for future studies on breast cancer.

### Conclusion

We summarized the diagnostic and therapeutic roles of twenty-seven miRNAs. Given the heterogeneity and complexity of breast cancer, the use of diagnosis and therapy based on miRNA appears intriguing since they are involved in controlling numerous dysregulated genes or pathways concurrently. This systematic review found strong evidence for the use of miRNAs as diagnostic and therapeutic biomarkers in breast cancer not only in early detection, but could be utilized to increase the survival rate of patients. Future investigations are required specifically to develop these biomarkers in a clinical setting. However, the key challenge for the forthcoming development of these therapeutic biomarkers is to broaden the research on miRNAs based on a better understanding of their targets to give a more inclusive picture of the biochemical pathways that they potentially control.

### REFERENCES

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021; 71: 209-49. doi: 10.3322/caac.21660
- Costa B, Amorim I, Gärtner F, Vale N. Understanding breast cancer: From conventional therapies to repurposed drugs. *European Journal of Pharmaceutical Sciences*. 2020; 151: 105401. doi: 10.1016/j.ejps.2020.105401
- Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. *American journal of cancer research*. 2015; 5: 2929-43.
- Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, et al. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. *Molecular cancer*. 2016; 15: 1-16. doi: 10.1186/s12943-016-0517-3
- Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. *Nature Reviews Cancer*. 2007; 7: 309-15.
- Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. *Annual review of medicine*. 2009; 60: 167-79.
- Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nature reviews cancer*. 2006; 6: 857-66. doi: 10.1038/nrc1997
- Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? *Cancer and metastasis reviews*. 2009; 28: 369-78. doi: 10.1007/s10555-009-9188-5
- Asiاف A, Ahmad ST, Arjumand W, Zargar MA. MicroRNAs in breast cancer: diagnostic and therapeutic potential. *MicroRNA and Cancer: Methods and Protocols*. 2018: 23-43.
- Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and epigenetics strategies to reverse breast cancer. *Cells*. 2019; 8: 1214. doi: 10.3390/cells8101214
- Subirana M, Solá I, Garcia JM, Gich I, Urrútia G. A nursing qualitative systematic review required MEDLINE and CINAHL for study identification. *Journal of clinical epidemiology*. 2005; 58: 20-5.
- Qattan A, Intabli H, Alkhayal W, Eltabache C, Tweigieri T, Amer SB. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. *BMC cancer*. 2017; 17: 799. doi: 10.1186/s12885-017-3776-5
- Monroig-Bosque PDC, Shah MY, Fu X, Fuentes-Mattei E. OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. 2018; 8: 13106. doi: 10.1038/s41598-018-30989-3
- Kassem NM, Makar WS, Kassem HA. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients. 2019; 20: 2749-2755. doi: 10.31557/apjcp.2019.20.9.2749
- Garrido-Cano I, Constâncio V, Adam-Artigues A, Lameirinhas A, Simón S, Ortega B, et al. Circulating mir-99a-5p expression in plasma: a potential biomarker for early diagnosis of breast cancer. *International Journal of Molecular Sciences*. 2020; 21: 7427. doi: 10.3390/ijms21197427
- Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L,

- Bachelot T, et al. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. *Breast cancer research*. 2015; 17: 1-20. doi: 10.1186/s13058-015-0515-1
17. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, et al. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. *Modern Pathology*. 2016; 29: 330-46. doi: 10.1038/modpathol.2016.38
  18. Patel Y, Shah N, Lee JS, Markoutsas E, Jie C, Liu S, et al. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. *Oncotarget*. 2016; 7: 18295-308. doi: 10.18632/oncotarget.7577
  19. Kim HY, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. *Cancer letters*. 2018; 415: 30-9. doi: 10.1016/j.canlet.2017.11.039
  20. Lyu H, Wang S, Huang J, Wang B, He Z, Liu B. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. *Cancer letters*. 2018; 420: 97-108. doi: 10.1016/j.canlet.2018.01.065
  21. Li WJ, Xie XX, Bai J, Wang C, Zhao L, Jiang DQ. Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. *European review for medical and pharmacological sciences*. 2018; 22: 8374-82. doi:10.26355/eurrev\_201812\_16535
  22. Chen X, Chen J. miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway. *Oncology research*. 2018; 26: 363-72. doi: 10.3727/096504017x14953948675421
  23. Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, et al. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer. *Theranostics*. 2019; 9: 1401-16. doi: 10.7150/thno.30701
  24. Zhang X, He Q, Sun L, Zhang Y, Qin S, Fan J. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers. 2019; 2019: 6057280. doi: 10.1155/2019/6057280
  25. Aakko S, Straume AH, Birkeland EE, Chen P, Qiao X, Kallio MJ, et al. MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells. *Translational Oncology*. 2019; 12: 170-9. doi: 10.1016/j.tranon.2018.10.001
  26. Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. *Molecular cancer*. 2019; 18: 1-5. doi: 10.1186/s12943-019-0988-0
  27. Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg AL. A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. 2020; 80: 418-29. doi: 10.1158/0008-5472.can-19-0656
  28. Cava C, Novello C, Martelli C, Dico AL, Ottobrini L, Piccotti F, et al. Theranostic application of miR-429 in HER2+ breast cancer. *Theranostics*. 2020; 10: 50-61. doi: 10.7150/thno.36274
  29. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer cell*. 2014; 25: 501-15. doi: 10.1016/j.ccr.2014.03.007
  30. Sun LL, Wang J, Zhao ZJ, Liu N, Wang AL, Ren HY, et al. Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2. *Oncology reports*. 2014; 31: 2085-92. doi: 10.3892/or.2014.3105
  31. Mollainezhad H, Eskandari N, Pourazar A, Salehi M, Andalib A. Expression of microRNA-370 in human breast cancer compare with normal samples. *Advanced biomedical research*. 2016; 5: 129. doi: 10.4103/2277-9175.186987
  32. Chen H, Pan H, Qian Y, Zhou W, Liu X. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. *Molecular cancer*. 2018; 17: 1-1. doi: 10.1186/s12943-017-0754-0
  33. Han M, Wang Y, Guo G, Li L, Dou D, Ge X, et al. MicroRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway. *Journal of Cellular Biochemistry*. 2018; 119: 8138-45. doi: 10.1002/jcb.26767
  34. Colombié M, Jézéquel P, Rubeaux M, Frenel JS, Bigot F, Seegers V, et al. The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients. *BMC cancer*. 2021; 21: 333. doi: 10.1186/s12885-021-08060-8
  35. Tutar Y. miRNA and cancer; computational and experimental approaches. *Current pharmaceutical biotechnology*. 2014; 15: 429. doi: 10.2174/138920101505140828161335
  36. Qadir MI, Faheem A. miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer. *Critical reviews in eukaryotic gene expression*. 2017; 27: 197-204. doi: 10.1615/CritRevEukaryotGeneExpr.2017019494
  37. Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, et al. Effect of exosomal miRNA on cancer biology and clinical applications. *Molecular cancer*. 2018; 17: 1-9. doi: 10.1186/s12943-018-0897-7
  38. Shen Z, Zhou R, Liu C, Wang Y, Zhan W, Shao Z, Liu J, et al. MicroRNA-105 is involved in TNF- $\alpha$ -related tumor microenvironment enhanced colorectal cancer progression. *Cell death & disease*. 2017; 8: 3213. doi: 10.1038/s41419-017-0048-x
  39. Gao R, Wang Z, Liu Q, Yang C. MicroRNA-105 plays an independent prognostic role in esophageal cancer and acts as an oncogene. *Cancer biomarkers : section A of Disease markers*. 2020; 27: 173-180. doi: 10.3233/cbm-180
  40. Jin X, Yu Y, Zou Q, Wang M, Cui Y, Xie J, et al. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1. *Journal of cellular biochemistry*. 2019; 120: 5880-88.
  41. Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple

- negative breast cancer. *Breast cancer research : BCR*. 2017; 19: 1-4. doi: 10.1186/s13058-017-0918-2
42. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. *Molecular and cellular biology*. 1998; 18: 558-65. doi: 10.1128/mcb.18.1.558
  43. Cao X, Liu D, Yan X, Zhang Y, Yuan L, Zhang T, et al. Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor. *FEBS letters*. 2013; 587: 639-44. doi: 10.1016/j.febslet.2013.01.012
  44. Xu WP, Yi M, Li QQ, Zhou WP, Cong WM, Yang Y, et al. Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma. *Hepatology (Baltimore, Md)*. 2013; 58: 1977-91. doi: 10.1002/hep.26541
  45. An F, Yamanaka S, Allen S, Roberts LR, Gores GJ, Pawlik TM, et al. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. *PLoS one*. 2012; 7: e45606. doi: 10.1371/journal.pone.0045606
  46. Wu Z, Sun H, Zeng W, He J, Mao X. Upregulation of MicroRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. *PLoS one*. 2012; 7: e45825. doi: 10.1371/journal.pone.0045825
  47. Lo SS, Hung PS, Chen JH, Tu HF, Fang WL, Chen CY, et al. Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma. *Oncogene*. 2012; 31: 226-37. doi: 10.1038/onc.2011.226
  48. Mao B, Zhang Z, Wang G. BTG2: a rising star of tumor suppressors (review). *International journal of oncology*. 2015; 46: 459-64. doi: 10.3892/ijo.2014.2765
  49. Chu TY, Yang JT, Huang TH, Liu HW. Crosstalk with cancer-associated fibroblasts increases the growth and radiation survival of cervical cancer cells. *Radiation research*. 2014; 181: 540-7. doi: 10.1667/rr13583.1
  50. Wang G, Li X, Tian W, Wang Y, Wu D, Sun Z, et al. Promoter DNA methylation is associated with KLF11 expression in epithelial ovarian cancer. *Genes, chromosomes & cancer*. 2015; 54: 453-62. doi: 10.1002/gcc.22257
  51. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*. 2007; 449: 682-8. doi: 10.1038/nature06174
  52. Xiao H, Li H, Yu G, Xiao W, Hu J, Tang K, et al. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. *Oncology reports*. 2014; 31: 1832-8. doi: 10.3892/or.2014.3048
  53. Ma L. Role of miR-10b in breast cancer metastasis. *Breast Cancer Research*. 2010; 12: 210. doi: 10.1186/bcr2720
  54. De Cola A, Lamolinara A, Lanuti P, Rossi C, Iezzi M, Marchisio M, et al. MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. *Cell Death and Disease*. 2018; 9: 821.
  55. Conde J, Oliva N, Atilano M, Song HS, Artzi N. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. *Nature Materials*. 2016; 15: 353-63. doi: 10.1038/nmat4497
  56. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. *Future medicinal chemistry*. 2014; 6: 1967-84. doi: 10.4155/fmc.14.116
  57. Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. *Cell Death and Disease*. 2014; 5: e1327. doi: 10.1038/cddis.2014.270
  58. Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, et al. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. *Biomaterials*. 2019; 210: 25-40. doi: 10.1016/j.biomaterials.2019.04.025
  59. Hau A, Ceppi P, Peter ME. CD95 is part of a let-7/p53/miR-34 regulatory network. *PLoS One*. 2012; 7: e49636. doi: 10.1371/journal.pone.0049636
  60. Imani S, Wei C, Cheng J, Sawada T, Akashi H, Inoue M, et al. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. *Oncotarget*. 2017; 8: 21362-79. doi: 10.18632/oncotarget.15214
  61. Lujambio A, Calin GA, Villanueva A, Rofero S, Sazeh Cesfendes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105: 13556-61. doi: 10.1073/pnas.0803055105
  62. Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ, Markey MP. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. *PLoS One*. 2012; 7: e42034. doi: 10.1371/journal.pone.0042034
  63. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*. 2007; 449: 682-88. doi: 10.1038/nature06174
  64. Medimegh I, Omrane I, Privat M, Uhrhammer N, Ayari H, Belaiba F, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. *PLoS One*. 2014; 9: e111877. doi: 10.1371/journal.pone.0111877
  65. Yoo B, Kavishwar A, Wang P, Ross A, Pantazopoulos P, Dudley M, et al. Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer. *Scientific Reports*. 2017; 7: 45060. doi: 10.1038/srep45060
  66. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2013; 19: 4477-87. doi: 10.1158/1078-0432.ccr-12-3401